Product Name: Fgr (6-25)
Product Number: PE-01BCW90
| Size: | 1 mg | Price: | 112.00 | |
| 5 mg | $US | 264.00 | ||
| 20 mg | 416.00 |
Peptide Name: Fgr (6-25)
Product Use: Services as a blocking peptide for use with the Fgr-ANT rabbit polyclonal antibody (Cat. No.: AB-NK268-1) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CKKLEPVATAKEDAGLEGDF
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2120.3 Da
Peptide Purity Percent after Synthesis and Purification: 90
Product Use: Services as a blocking peptide for use with the Fgr-ANT rabbit polyclonal antibody (Cat. No.: AB-NK268-1) that is also available from Kinexus. The peptide sequence is located in the post-N-terminus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CKKLEPVATAKEDAGLEGDF
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2120.3 Da
Peptide Purity Percent after Synthesis and Purification: 90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Fgr pan-specific antibody (Cat. No.: AB-NK268-1)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Fgr pan-specific antibody (Cat. No.: AB-NK268-1)
Scientific Background: Fgr is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor kinase that transmits signals from cell surface receptors and regulates immune responses. In addition, it functions as positive regulator of cell migration and regulates cytoskeleton reorganization. Fgr appears to be an oncoprotein (OP). A Y523F mutation in Fgr is associated with strongly increased catalytic activity, which can be oncogenic and promote abnormal cell proliferation. Fgr oncogene mRNA was found to be induced in B lymphocytes by Epstein-Barr virus infection.
© Kinexus Bioinformatics Corporation 2017